Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002334 · ClinicalTrials.gov registry record · Phase 3
A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 3
- Development phase
- 3,000
- Enrollment target
NCT00002334 is a Phase 3 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 3,000 participants.
The verdict
NCT00002334, a Phase 3 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 3,000 participants
- Enrollment target
Study Summary
To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
Interventions
- DRUG Zidovudine
- DRUG Saquinavir
- DRUG Zalcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,000 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002334
The ClinicalTrials.gov registry entry for NCT00002334 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 3,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Zidovudine is the first listed.
NCT00002334 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002334 about?
NCT00002334 is a clinical study titled "A Study of Zidovudine (AZT) Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Patients With Little or No Previous Treatment". To compare, in zidovudine (AZT)-naive patients, the safety, tolerance, and efficacy of saquinavir mesylate (Ro 31-8959) alone versus AZT alone versus AZT in combination with Ro 31-8959, zalcitabine (ddC), or both. To compare various disease markers among the different regimens.
What is the current status of trial NCT00002334?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 3,000 participants.
What interventions are being tested in trial NCT00002334?
The interventions under investigation include: Zidovudine (DRUG), Saquinavir (DRUG), Zalcitabine (DRUG).
Who is sponsoring clinical trial NCT00002334?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.